Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Aikobai's supplementary explanations regarding compliance of its implemented equity incentive plan and reasons for not completing its overseas listing after previous approval [1][2][3] Group 1: Regulatory Requirements - Aikobai is required to clarify the actual operations of its medical device production and business, including whether it has obtained the necessary qualifications and if its business scope involves areas listed in the "Negative List for Foreign Investment Access (2024 Edition)" [1] - The company must provide details on the regulatory procedures for overseas investments and foreign exchange management related to its overseas subsidiaries, along with a conclusive opinion on compliance [1] - Aikobai needs to explain the compliance of its implemented equity incentive plan, including the composition of participants, their relationships with other stakeholders, and the fairness of pricing and decision-making processes [1] Group 2: Listing Status - The company must explain the reasons for not completing its overseas listing after previous approval [3] - Aikobai is also required to provide details on its prior A-share listing guidance and the reasons for withdrawal, including whether it plans to continue pursuing A-share listing and any potential impacts on the current issuance [3] Group 3: Company Overview - Aikobai, established in 2013, is a biopharmaceutical company focused on discovering and developing therapies for respiratory and pediatric diseases [3] - The company has developed a pipeline of six candidate drugs, including its core product Qiruisuo Wei, which targets respiratory syncytial virus (RSV) infections, and other drugs in various clinical stages for conditions such as idiopathic pulmonary fibrosis (IPF) and attention deficit hyperactivity disorder (ADHD) [3]
新股消息 | 爱科百发拟港股上市 中国证监会要求补充说明已实施股权激励方案的合规性等
智通财经网·2025-10-31 13:40